=== Population Extract 1 (Population) ===
sur. Induction chemoradiation and 3488–515.
surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad-
long-term results of Southwest Oncology Group Trial 9416 – (Inter- vanced non-small cell lung cancer in the elderly population. Cochrane
group Trial 0160). J Clin Oncol 2007;25:313–8. Database Syst Rev 2015;(10):CD010463.
19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung
ment for microscopic residual disease after non-small ce

=== Population Extract 2 (Patients) ===
Smjernice
Guidelines
SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE
BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING
PATIENTS WITH NON-SMALL CELL LUNG CANCER
MIROSLAV SAMARŽIJA, MARKO JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ,
INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN SEIWERTH,
SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ,
SILVANA SMOJVER JEŽEK, DINKO STANČIĆ-ROKO

=== Population Extract 3 (Patients) ===
of the most common female cancers. Non-small cell
lung cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and monitoring
of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic therapy and
immunotherapy according to the stage, specifi c tumour histological subtype and patient condition.
Liječ Vjesn 2017;139:365–371
Smjernice za dijagnozu, liječenje i praćenje bolesnika
* Klinika za plućne

=== Population Extract 4 (Patients) ===
čkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin On-
prema preporuci multidisciplinarnog tima). col 2012;30:172–8.
8. Gilligan D, Nicolson M, Smith I i sur. Preoperative chemotherapy in
Diseminirana/neresektabilna lokalno uznapredovala patients with resectable non-small cell lung cancer: results of the MRC
bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up-
date of systematic review. Lancet 2007;369:1929–37.
detekcije progresije bolesti
9. NSCLC Meta-analysis Collaborative Gro

=== Population Extract 5 (Patients) ===
33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing
12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo-
radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51.
13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall
versus s

=== Population Extract 6 (Patients) ===
ll lung cancer. J Tho-
small cell lung cancer. J Clin Oncol 2010;28:2181–90.
rac Oncol 2010;5:1416–23.
17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide-
38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage
lines on fitness for radical therapy in lung cancer patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On-
chemo-radiotherapy). Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33:
18. Rusch VW, Giroux DJ, Kraut MJ i sur. Induction chemoradiation and 3488–515.
surgical resection for super

=== Population Extract 7 (Patients) ===
tice Guidelines for diagnosis, treatment
surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27.
20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy
tion therapy on survival in patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life
II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006;
apy: the adjuvant Navelbine International Trialist A

=== Population Extract 8 (Patients) ===
ant Navelbine International Trialist Association (ANITA) 95:966–73.
Randomized Trial. Int J Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi-
21. Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive after two cycles of
adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non small-cell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy

=== Population Extract 9 (Patients) ===
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a
vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;
resected stage IB

=== Population Extract 10 (Patients) ===
13:239–46.
analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che-
23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX-
cisplatin versus observation in patients with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two
IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51.
Trialist Association [ANITA]): a randomised controlled trial. Lancet 45.

=== Population Extract 11 (Patients) ===
taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10):
24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin
46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst-
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared with observatio

=== Population Extract 12 (Patients) ===
2011;12(8):
plus carboplatin compared with observation in stage IB non-small-cell
lung cancer: CALGB 9633 with the Cancer and Leukemia Group B,
47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat-
Radiation Therapy Oncology Group, and North Central Cancer Treat-
ment for patients with advanced non-small-cell lung cancer with acti-
ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51.
vating epidermal growth factor receptor mutation: Review of the evi-
26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57.
citabine p

=== Population Extract 13 (Patients) ===
8380–8. analysis. J Natl Cancer Inst 2013;105:595–605.
27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as
agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la-
28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44.
tio

=== Population Extract 14 (Patients) ===
ne crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer
non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2

=== Population Extract 15 (Patients) ===
;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer
non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65.
Study Group. J Clin

=== Population Extract 16 (Patients) ===
9:255–65.
Study Group. J Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme-
56. Sheperd FA, Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40.
cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for
Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer
57. Hanna N, Sheperd FA, Fosse

=== Population Extract 17 (Patients) ===
l GM, Chen H i sur. FDA Approval: Alectinib for
Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer
57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non-
1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–

=== Population Extract 18 (Patients) ===
pherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously
lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353:
59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32.
sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. tabase Syst Re

